Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas



Status:Recruiting
Conditions:Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/23/2018
Start Date:May 2013
End Date:May 2020

Use our guide to learn which trials are right for you!

Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas

MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes.
Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas,
known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b
(mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue.
This study tests the hypothesis that in primary glioma samples mir-10b expression patterns
will serve as a prognostic and diagnostic marker. This study will also characterize the
phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the
critical function of anti-mir-10b in blocking established glioblastoma growth, the
investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b
treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients
diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b
expression levels. Patient survival, as well as tumor grade and genotypic variations will be
correlated to mir-10b expression levels.


Inclusion/Exclusion Criteria:

- 18 years of age

- Brain tumor(s) to be resected for clinical reasons.

- Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III
or IV.

- Adequate tissue available for processing as determined by Pathology.

- Adequate decision making ability to review, discuss and sign a consent form to allow
their tumor samples to be used for future human brain tumor biology laboratory
research. Determination of capacity to consent is made by one of the co-investigators
based on clinical assessment.

- Patients opting for the standard treatment regimen for their disease as well as
ongoing clinical trials will be are eligible to participate in this study. Standard
care for newly-diagnosed glioblastomas typically consists of surgical resection
followed by radiotherapy with concomitant temozolomide, followed by adjuvant
temozolomide chemotherapy.
We found this trial at
4
sites
85 S Prospect St
Burlington, Vermont 5405
(802) 656-3131
Phone: 802-656-4909
University of Vermont The University of Vermont combines faculty-student relationships most commonly found in a...
?
mi
from
Burlington, VT
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Phone: 617-636-2883
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
?
mi
from
Boston, MA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Phone: 617-643-4395
?
mi
from
Boston, MA
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Arti B Gaur, PhD
Phone: 800-639-6918
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials